Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.85 -0.1%	$18.73	$13.52 ▼ $35.25	$1.71B	2.22	2.47 million shs	1.74 million shs
CDTX Cidara Therapeutics	$65.23 -0.2%	$57.18	$10.14 ▼ $69.36	$1.66B	1.18	453,173 shs	298,680 shs
IMCR Immunocore	$32.24 -1.3%	$33.33	$23.15 ▼ $39.33	$1.65B	0.77	314,797 shs	242,469 shs
IVA Inventiva	$6.35 +21.4%	$3.59	$1.53 ▼ $6.50	$500.31M	0.73	37,090 shs	252,015 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-0.06%	+5.25%	-15.45%	+7.05%	-35.32%
CDTX Cidara Therapeutics	-0.24%	-3.35%	+5.33%	+195.69%	+402.16%
IMCR Immunocore	-1.26%	-1.32%	-4.92%	-11.65%	-10.79%
IVA Inventiva	+21.41%	+49.06%	+101.59%	+102.81%	+165.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.04 of 5 stars	3.5	0.0	0.0	2.2	2.5	0.6
CDTX Cidara Therapeutics	3.6357 of 5 stars	2.6	3.0	4.6	2.7	1.7	0.0
IMCR Immunocore	1.5813 of 5 stars	3.3	1.0	0.0	1.7	2.5	0.0
IVA Inventiva	3.184 of 5 stars	3.4	5.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.45	187.56% Upside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-1.67% Downside
IMCR Immunocore	2.55	Moderate Buy	$56.89	76.45% Upside
IVA Inventiva	2.83	Moderate Buy	$13.00	104.72% Upside

Current Analyst Ratings Breakdown

Latest IVA, BEAM, CDTX, and IMCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
8/25/2025	IMCR Immunocore	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$48.00
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$60.27M	28.28	N/A	N/A	$10.35 per share	1.63
CDTX Cidara Therapeutics	$1.27M	1,302.55	N/A	N/A	$19.76 per share	3.30
IMCR Immunocore	$310.20M	5.24	N/A	N/A	$7.71 per share	4.18
IVA Inventiva	$9.95M	61.05	N/A	N/A	($1.21) per share	-5.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)

Latest IVA, BEAM, CDTX, and IMCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2025	Q2 2025	IVA Inventiva	-$0.41	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	5.34%	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	6.75	6.75
CDTX Cidara Therapeutics	N/A	16.45	16.45
IMCR Immunocore	1.01	5.89	5.86
IVA Inventiva	N/A	0.92	0.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CDTX Cidara Therapeutics	35.82%
IMCR Immunocore	84.50%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
CDTX Cidara Therapeutics	3.89%
IMCR Immunocore	10.40%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable

IVA, BEAM, CDTX, and IMCR Headlines

Recent News About These Companies

Inventiva (NASDAQ:IVA) Trading 4.3% Higher - What's Next?

August 28 at 2:05 AM | marketbeat.com

Inventiva initiated with an Overweight at Piper Sandler

August 27 at 8:39 PM | msn.com

Inventiva surges as Piper Sandler issues bullish view citing lead asset

August 27 at 8:39 PM | msn.com

Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 72.9%

August 17, 2025 | marketbeat.com

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

August 12, 2025 | finance.yahoo.com

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

August 3, 2025 | marketbeat.com

Half-Year Review of Inventiva’s Liquidity Contract with Kepler ...

August 2, 2025 | morningstar.comM

Inventiva Announces Preliminary First-Half 2025 Financial Results

July 31, 2025 | theglobeandmail.com

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

July 31, 2025 | globenewswire.com

INVENTIVA: Inventiva Reports Preliminary 2025 First-Half Financial Information

July 30, 2025 | finanznachrichten.de

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

July 30, 2025 | finance.yahoo.com

Inventiva appoints new R&D president and regulatory affairs executive

July 11, 2025 | investing.com

Inventiva names Jason Campagna as President of R&D and Chief Medical ...

July 11, 2025 | finance.yahoo.com

Inventiva Strengthens Leadership Team Ahead of Key MASH Drug Milestones

July 10, 2025 | yahoo.com

Inventiva reshuffles leadership as it pushes lanifibranor closer to approval

July 10, 2025 | thepharmaletter.comT

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

July 9, 2025 | globenewswire.com

INVENTIVA: Inventiva receives $10 million milestone payment from CTTQ

July 8, 2025 | finanznachrichten.de

Inventiva receives $10 million milestone payment from CTTQ

July 7, 2025 | globenewswire.com

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients ... - The Manila Times

July 4, 2025 | manilatimes.netM

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

July 2, 2025 | globenewswire.com

Inventiva S.A. (IVA) Latest Stock News & Headlines - Yahoo Finance

June 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IVA, BEAM, CDTX, and IMCR Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.85 -0.01 (-0.06%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$16.80 -0.05 (-0.33%)

As of 05:03 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Cidara Therapeutics NASDAQ:CDTX

$65.23 -0.16 (-0.24%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$65.19 -0.04 (-0.06%)

As of 08/28/2025 07:54 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Immunocore NASDAQ:IMCR

$32.24 -0.41 (-1.26%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$32.25 +0.01 (+0.03%)

As of 08/28/2025 07:59 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Inventiva NASDAQ:IVA

$6.35 +1.12 (+21.41%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$5.67 -0.68 (-10.71%)

As of 05:07 AM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time